Overview
NICE is unable to make a recommendation about the use in the NHS of ibrutinib with bendamustine and rituximab for treating relapsed or refractory chronic lymphocytic leukaemia after systemic therapy. This is because Janssen-Cilag did not provide an evidence submission.
Last reviewed: 22 March 2017
Next review: We will review this decision if the company decides to make a submission.